Skip to main content
. 2022 Jul 22;13:955825. doi: 10.3389/fmicb.2022.955825

Figure 4.

Figure 4

Sunburst of the contribution of nVFCs in SF3 and CK3 in OPLS-DA. a, steroids and steroid derivatives; b, sphingolipids; c, saccharolipids; d, prenol lipids; e, glycerophospholipids; f, glycerolipids; g, fatty Acyls; H, keto acids and derivatives; i, hydroxy acids and derivatives; j, carboxylic acids and derivatives; k, carboximidic acids and derivatives; l, Organooxygen compounds; m, pyrrolidines; n, pyrroles; o, pyridines and derivatives; p, pyrans; q, pteridines and derivatives; r, oxepanes; s, naphthofurans; t, lactones; u, indoles and derivatives; v, imidazopyrimidines; w, heteroaromatic compounds; x, dihydrofurans; y, diazines; z, benzotriazoles; aa, benzopyrans; ab, benzodioxoles; ac, azolidines; ad, stilbenes; ae, phenylpropanoic acids; af, macrolides and analogs; ag, Kavalactones; ah, isoflavonoids; ai, flavonoids; aj, diarylheptanoids; ak, coumarins and derivatives; al, cinnamic acids and derivatives; am, 2-arylbenzofuran flavonoids; an, phenols; ao, phenol ethers; ap, phenanthrenes and derivatives; aq, naphthalenes; ar, benzene and substituted derivatives; as, ribonucleoside 3′-phosphates; at, pyrimidine nucleotides; au, pyrimidine nucleosides; av., pyrimidine nucleosides; aw, organonitrogen compounds; ax, non-metal oxoanionic compounds; ay, morphinans.

HHS Vulnerability Disclosure